The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Mar 31, 2025•about 1 year ago
Contract Type
partnership
San DiegoBiotechnologyHealth CareTherapeutics
Description
Calidi Biotherapeutics, Inc. announced the closing of its previously announced registered direct offering and concurrent private placement, with gross proceeds of approximately $3.9 million. The company intends to use the net proceeds for working capital, general corporate purposes, and to advance its pre-clinical development programs.
Company Information
Company
Calidi Biotherapeutics
Location
San Diego, California, United States
About
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.
San DiegoBiotechnologyHealth CareTherapeutics